Targeting two cancer cell defenses may offer new treatment strategy

· News-Medical

Cancer cells must protect themselves from the harmful substances they produce as they grow. Now, researchers have identified how they neutralize one of these substances, formaldehyde, while keeping another defence against cell death intact. The findings suggest a way to attack both defenses together, and the next step is to find out whether it could become a treatment.

Formaldehyde is produced naturally inside cells and can damage DNA by binding it to nearby proteins. Cells neutralize it using glutathione, a molecule that protects against chemical damage. Glutathione also prevents ferroptosis, a form of cell death caused by damage to fats in the cell membrane. Both tasks depend on the same supply of glutathione, so using it to deal with formaldehyde can leave less available for the other task. The study explains how cancer cells can maintain both defences.

The research, led by Lucas Pontel's group at the Josep Carreras Leukaemia Research Institute, focused on a protein called NRF2. Often overactive in tumours, NRF2 controls a process that helps cancer cells neutralise formaldehyde while preserving their glutathione supply.

How cancer cells preserve their defenses

NRF2 increases production of SLC7A11, a protein that transports a molecule called cystine into cells. Once inside, cystine is converted into cysteine, which can react directly with formaldehyde without using glutathione. This reaction produces a stable compound called thioproline, which the researchers detected in cancer cells. By taking in more cystine, the cells can deal with formaldehyde and keep glutathione available to prevent ferroptosis.

Blocking both defenses

Blocking SLC7A11 in cells exposed to high levels of formaldehyde stopped protein production and triggered cell death. The researchers also used drugs to block both cystine uptake and glutathione production. This combination killed leukemia cells, as well as various types of solid tumors such as lung and colon cancers and brain tumor cells.

What this could mean for leukemia

The results suggest that targeting both defenses could be worth investigating as a treatment approach for leukemia. In patients with myeloid leukemia, higher levels of SLC7A11 are associated with poorer survival. This raises the possibility that these cancers depend on the defense system identified in the study. The team now plans to investigate whether blocking it could lead to a safe and effective treatment.

The study also involved Dr Gael Roué's group at the Josep Carreras Institute and researchers from the University of Leicester (United Kingdom), the Institute of Biomedicine of Buenos Aires (IBioBA-MPSP, Argentina) and the International University of Catalonia (UIC).

Source:

Josep Carreras Leukaemia Research Institute

Journal reference: